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Evaluation of plitidepsin in patients with primary
myelofibrosis and post polycythemia vera/essential
thrombocythemia myelofibrosis: results of preclinical studies
and a phase II clinical trial
A Pardanani1, A Tefferi1, P Guglielmelli2, C Bogani2, N Bartalucci2, J Rodríguez3, S Extremera3, I Pérez3, V Alfaro3 and AM Vannucchi2
Previous data established that plitidepsin, a cyclic depsipeptide, exerted activity in a mouse model of myelofibrosis (MF). New
preclinical experiments reported herein found that low nanomolar plitidepsin concentrations potently inhibited the proliferation
of JAK2V617F-mutated cell lines and reduced colony formation by CD34+ cells of individuals with MF, at least in part through
modulation of p27 levels. Cells of MF patients had significantly reduced p27 content, that were modestly increased upon plitidepsin
exposure. On these premise, an exploratory phase II trial evaluated plitidepsin 5 mg/m2 3-h intravenous infusion administered on
days 1 and 15 every 4 weeks (q4wk). Response rate (RR) according to the International Working Group for Myelofibrosis Research
and Treatment consensus criteria was 9.1% (95% CI, 0.2–41.3%) in 11 evaluable patients during the first trial stage. The single
responder achieved a red cell transfusion independence and stable disease was reported in nine additional patients (81.8%).
Eight patients underwent a short-lasting improvement of splenomegaly. In conclusion, plitidepsin 5 mg/m2 3-h infusion q4wk was
well tolerated but had a modest activity in patients with primary, post-polycythaemia vera or post-essential thrombocythaemia MF.
Therefore, this trial was prematurely terminated and we concluded that further clinical trials with plitidepsin as single agent in MF
are not warranted.
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INTRODUCTION
Primary myelofibrosis (PMF) and post-polycythaemia vera (post-PV
MF) or post-essential thrombocythaemia myelofibrosis (post-ET
MF) comprise a heterogenous group of chronic myeloproliferative
neoplasms with no curative therapeutic modality at present
except for allogeneic stem cell transplantation.1–3 They are
characterised by expansion of a clonal haematopoietic stem cell
population leading to a bone marrow fibrosis and impaired
haematopoiesis resulting in severe anaemia, massive splenome-
galy and extramedullary haematopoiesis along with the presence
of severe constitutional symptoms. At present only one drug,
ruxolitinib, has been approved primarily based on its ability to
reduce splenomegaly and improvement of disease-related
symptoms.4,5 Therefore, agents with activity in this group of
malignancies are needed.
Plitidepsin (Aplidin) is a cyclic depsipeptide originally isolated
from the Mediterranean tunicate Aplidium albicans and currently
produced by chemical synthesis.6 Plitidepsin was evaluated in a
murine model of myelofibrosis (MF), the Gata-1(low) mice.7
Treatment with plitidepsin increased the platelet count in blood
and marrow cellularity in the femur, and reduced the vessel
density and expression of transforming growth factor-beta,
vascular endothelial growth factor and thrombopoietin.8,9 There-
fore, plitidepsin ameliorated some of the traits of the myelofibrotic
phenotype expressed by Gata-1(low) mice. In particular, the
observed inhibition of transforming growth factor-beta and
vascular endothelial growth factor expression, associated with
reduced microvessel density, suggested a possible activity of
plitidepsin in human MF, where levels of these two cytokines are
abnormally increased.8,9 The aforementioned data supported this
drug as candidate for clinical evaluation in MF. Consequently, an
exploratory phase II clinical trial was designed to evaluate the
efficacy and safety of plitidepsin in patients with PMF, post-PV MF
or post-ET MF (ClinicalTrials.gov identifier: NCT01149681). We also
report herein new preclinical data obtained in cellular models of
MF, including cell lines and primary patients’ cells.
MATERIALS AND METHODS
Preclinical studies
Plitidepsin was provided by PharmaMar, dissolved in DMSO and stored in
aliquots at − 20 °C. For in vitro studies, we used the following human cell
lines: HEL, UKE-1 and SET2 (JAK2V617F mutated) and K562 (BCR/ABL1
mutated), and the murine Ba/F3 cell lines overexpressing the wild-type or
V617F-mutated JAK2. Primary cells were obtained from patients with PMF,
diagnosed according to the 2008 World Health Organization (WHO)
criteria, under a protocol approved by the Institutional Review Board of
Azienda Ospedaliera-Universitaria Careggi and after obtaining an informed
consent. Normal CD34+ cells were obtained from healthy donors for
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transplantation purposes who agreed to donate the excess CD34+ cells,
after providing an informed consent. Research was carried out according
to the principles of the Declaration of Helsinki.
The drug-induced inhibition of cell growth by plitidepsin in human and
mouse cell lines were measured by both a short-term microwell
proliferation assay and a long-term clonogenic assay in agar. Quantification
of apoptotic cells and assessment of the cell cycle distribution was
accomplished by flow cytometry. Colony formation by CD34+ cells from
MF patients and healthy controls in the presence of plitidepsin was
measured in methylcellulose media for burst forming unit erythroid
(BFU-E) and colony forming unit granulocyte-macrophage (CFU-GM) and in
Megacult Collagen and medium with lipids for colony forming unit-
megakaryocyte (CFU-Mk). The effects of plitidepsin exposure on the
expression and phosphorylation of intracellular proteins were evaluated by
western blot electrophoresis. Measurement of selected messenger RNAs
(mRNAs) was performed by real-time PCR. A detailed description of the
methods employed is provided in Supplementary Material.
Patients
Patients were recruited at one investigational site each in the USA and
Italy. The study protocol was approved by the Independent Local Ethics
Committee of each participating centre and was conducted in accordance
with the Declaration of Helsinki, Good Clinical Practice guidelines and local
regulations on clinical trials. Signed informed consent was obtained from
all patients prior to any study-specific procedure.
Eligibility criteria
Eligibility criteria included patients ⩾ 18-years old with diagnosis of PMF or
post-polycythemia vera (PV) MF or post-essential thrombocythemia (ET)
MF, as per the revised World Health Organization criteria;10 high-risk or
intermediate-2 MF risk, as defined by the International Prognostic Scoring
System,11,12 or intermediate-1 MF risk associated with symptomatic
splenomegaly/hepatomegaly and/or unresponsive to available therapy;
life expectancy ⩾ 12 weeks; Eastern Cooperative Oncology Group
performance status ⩽ 2; and adequate organ function within 7 days prior
to start the study treatment.
Patients were excluded if they had received chemotherapy, immuno-
modulatory drug therapy, immunosuppressive therapy, corticosteroids4
10mg/day prednisone or equivalent or erythropoietin within 2 weeks prior
to the study treatment onset; incomplete recovery from surgery or
radiotherapy within the 4 prior weeks; previous treatment with doxorubicin
at cumulative doses⩾ 450mg/m2; history of prior malignancies within last 3
years (except for early-stage basal cell or squamous cell skin cancer, cervical
intraepithelial neoplasia, cervical carcinoma in situ or superficial bladder
cancer); grade 42 myopathy or any clinical situation causing a persistent
elevation of creatine phosphokinase; acute infection; and active liver disease,
or any other unstable or serious medical condition (for example,
uncontrolled arterial hypertension, myocardial infarction, cerebrovascular
accident, valvular heart disease, symptomatic arrhythmia, so on). Patients
were also excluded if they were pregnant or breast-feeding women, or if
they were not using appropriate contraceptive measures.
Treatment
Plitidepsin was given at the dose of 5 mg/m2 intravenously (i.v.) over 3 h on
days 1 and 15 every 4 weeks (q4wk), for a maximum of 6 cycles.
Prophylactic medication 20–30min before each plitidepsin infusion
consisted of dexamethasone 8mg i.v., ondansentron 8 mg i.v. (granisetron
3mg i.v. preferred when available), diphenhydramine hydrochloride 25mg
i.v., and ranitidine 50mg i.v., or their equivalents. Additional prophylactic
medication (metoclopramide and/or extended oral ondansetron) could be
used if required. Plitidepsin treatment could be continued for more than
six cycles when considered of clinical benefit for the patient.
A maximum of two plitidepsin dose reductions (from 5.0 to 4.0, then to
3.2 mg/m2) were allowed in case of any of the following events: grade 4
neutropenia lasting47 days or accompanied by infection/fever; grade 4
thrombocytopenia lasting47 days or accompanied by major bleeding;
grade⩾ 3 nausea/vomiting or diarrhoea refractory to standard therapy;
grade⩾ 3 muscular toxicity; grade⩾ 2 peripheral neuropathy; grade⩾ 3
transaminase increase42 weeks, or any toxicity causing a dose delay of
1–2 weeks; grade⩾ 2 direct bilirubin increase; grade⩾ 3 CPK increase; or
any other grade⩾ 3/4 non-haematological toxicity related to the study
treatment (excluding grade⩾ 3 hypersensitivity reactions, grade 3
asthenia/ fatigueo5 days or grade 3 diarrhoea o1day).
Efficacy assessment
The primary efficacy endpoint was response rate (RR) according to the
International Working Group for Myelofibrosis Research and Treatment
consensus criteria.13 Thus, a confirmed response included complete
remission or partial remission, or clinical improvement that persisted for
a minimum 8-week period. Efficacy was evaluated at the beginning of each
plitidepsin cycle, independently of dose delays, up to 6 cycles of treatment.
Progression-free survival and overall survival were also assessed as
exploratory efficacy parameters.
Safety assessment
Safety was evaluated in all patients who received at least one plitidepsin
infusion, complete or incomplete, by assessment of adverse events (AEs),
clinical laboratory test results, physical examinations and vital signs. AEs
were recorded and coded with the Medical Dictionary for Regulatory
Activities, v.12.0. AEs and laboratory values were graded according to the
National Cancer Institute-Common Toxicity Criteria for Adverse Events
NCI-CTCAE, v. 4.0. All patients were followed until recovery from any
plitidepsin-related AE.
Statistical methods
A Simon’s optimal two-stage design14 was adopted. In a first stage, a
minimum of 10 evaluable patients were to be accrued to test the null
hypothesis, Ho: RR⩽ 15% versus Ha: RR⩾ 35% (alpha⩽ 0.1 and beta⩽ 0.1).
At this first step, the largest RR to consider the study treatment as
ineffective was 10%, and the smallest RR to consider the treatment worthy
of further study was 20%. If the latter occurred, 35 additional evaluable
patients were to be recruited. An RR of at least 22.2% in the total of 45
patients was required to conclude that the study treatment was effective.
Descriptive statistics were used for this study. Non-continuous variables
are described in frequency tables using counts and percentages.
Continuous variables are described by median, minimum and maximum.
Binomial exact estimator and its 95% CI was calculated for the evaluation
of the main endpoint (RR according to International Working Group for
Myelofibrosis Research and Treatment) and other categorical efficacy
variables (for example, progression-free survival and progression-free
survival at fixed time points).
RESULTS
Preclinical studies: effects of plitidepsin in cellular models
We first measured the growth inhibitory activity of plitidepsin in
both a short-term liquid proliferation and a clonogenic assay. The
IC50 values are reported in Table 1. We observed that the
proliferation rate of HEL, UKE-1 and SET2 cells was inhibited at
very-low nanomolar concentrations of plitidepsin, yet comparable
with K562 cells; on the other hand, colony formation by UKE-1 and
SET2 cells was inhibited at 3–5-fold lower plitidepsin concentra-
tions compared with K562 cells. Murine Ba/F3 JAK2V617F cells
Table 1. Determination of plitidepsin IC50 in human and murine
JAK2V617F-mutated cell lines and controls
Cell line IC50 (nM)
WST-1 assay Clonogenic assay
K562 1.50± 0.10 2.70± 0.30
HEL 1.00± 0.30 1.50± 0.05
SET2 1.00± 0.30 0.80± 0.02**
UKE-1 2.40± 0.20 0.50± 0.03**
Ba/F3 JAK2 wild-type 0.40± 0.03 ND
Ba/F3 JAK2 V167F 0.03± 0.01** ND
Abbreviations: IC50, plitidepsin concentration that reduced colony number
to 50% that measured in control dishes with vehicle only; ND, not done.
IC50 value was calculated using both short-term proliferation assay in liquid
cultures and long-term clonogenic assay in agar. Control murine Ba/F3
wild-type cells were maintained in the presence of IL-3. **Po0.01.
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resulted significantly more sensitive to plitidepsin than the
wild-type counterpart in liquid assays (Table 1). Overall, these
data indicate that plitidepsin inhibits proliferative activity of
JAK2V617F-mutated cells at very-low nanomolar concentrations.
The SET2 cell line only was later employed for assessing the effects
of plitidepsin on cell cycle and apoptosis. The proportion of SET2
cells undergoing cell death was determined by Annexin V staining.
As shown in Figure 1a, treatment with plitidepsin resulted in a
dose-dependent, statistically significant increase of Annexin
V-positive cells from 19.0 ± 2.1–25.0 ± 3.7% (Po0.05) and
49.0 ± 2.0% (Po0.01) at 1 and 5 nM, respectively. We found that
plitidepsin caused a dose-dependent accumulation of SET2 cells in
the G0/G1 phase of the cell cycle from 65.5 ± 3.5–71.5 ± 3.3% at
5 nM (Po0.05) and 78.0 ± 5.3% at 10 nM (Po0.01) (Figure 1b).
Similar results were obtained with HEL cells (not shown).
The effects of plitidepsin on the clonogenic potential of
haematopoietic progenitors from patients with myeloproliferative
neoplasms were assessed by using a semisolid medium. For this
purpose, CD34+ cells from JAK2V617F mutated (n=3) or JAK2 wild-
type (n=2) PMF patients, or healthy controls (n=5), were cultured
in the presence of cytokines supporting the growth of BFU-E, CFU-
G/GM or CFU-Mk. The drug was added once at the beginning of
culture at increasing concentrations up to 5 nM, and the IC50 was
calculated in comparison with the vehicle only. We found that the
formation of all colony types from PMF cells was inhibited at a
significantly lower concentration of plitidepsin compared to healthy
controls; the IC50 values for BFU-E, CFU-GM and CFU-Mk were
8.7 ± 2.3, 8.2 ± 3.5 and 1.7± 0.9 nM, respectively, in healthy controls
versus 1.1 ± 0.6 nM, 1.6 ± 0.4 and 0.4± 0.1 nM in PMF subjects; all the
differences were statistically significant (Po0.01).
To evaluate the effects on plitidepsin on downstream targets,
we used western blot analysis in extracts of SET2 cells that had
been exposed to varying concentration of the drug for 24 h. We
failed to observe any significant modulation in the levels of total
and phosphorylated forms of proteins involved in JAK/STAT
signalling such as JAK2, STAT5, STAT3, as well as Akt and 4eBP1,
GATA-1, Pim1 and Bcl-xL (Figure 2). On the other hand, we found a
significant upregulation of p27 at the highest dose (10 nM); such
an increase was due to plitidepsin acting at the transcriptional
level since the amount of p27 mRNA measured by real-time
quantitative PCR increased significantly in all myeloproliferative
neoplasm-derived cells exposed to the drug (Figure 3). Of note,
K562 appeared unresponsive to plitidepsin at this regard.
Since low p27 cellular levels have been associated with
response to plitidepsin in several cancer cells, we measured the
levels of p27 mRNA in CD34+ cells from PMF patients compared
with controls. As shown in Figure 4, we found that the p27 mRNA
content was significantly reduced in patients’ cells as compared
with healthy controls; however, exposure to up to 10 nM
plitidepsin of CD34+ cells from three PMF patients resulted in
minimal changes in p27 mRNA levels (not shown).
Phase II clinical trial
Patient characteristics. A total of 12 patients were included and
treated with plitidepsin between 8 July 2010 and 6 April 2011.
Their demographic and baseline characteristics are summarised in
Table 2. At time of diagnosis, 5 patients (42%) had PMF, 3 (25%)
had post-PV MF and 4 (33%) had post-ET MF. At the time of study
entry, most patients (n= 9, 75%) had high-risk disease according
Figure 1. Effect of plitidepsin on cell death and cell cycle in SET2
cells. In (a), the percentage of Annexin V-positive cells was
measured with Annexin V/propidium iodide staining and flow
cytometry in cultures of SET2 cells that had been exposed to varying
amount of plitidepsin for 48 h; cells incubated without the drug
served as control. *Po0.05; **Po0.01. In (b), the frequency of cells
in the G0/G1, S and M phase of the cell cycle was measured by flow
cytometry after propidium iodide staining of SET2 cells that had
been exposed to plitidepsin for 18 h, compared with control cells
with vehicle. Results shown are the mean± s.d. of three indepen-
dent experiments.
Figure 2. Effect of plitidepsin on the total protein expression and
protein phosphorylation of selected downstream signalling proteins
in SET2 cells. SET2 cells were incubated for 24 h with varying amount
of plitidepsin, as indicated. Total and phosphorylated proteins were
assayed by using specific antibodies and revealed by western
blotting. Shown is one representative of at least three independent
experiments for each protein target.
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to International Prognostic Scoring System. The spleen was
palpable in all patients, with splenomegaly⩾ 10 cm in 8 patients
(67%). Hepatomegaly was present in 4 patients. All 12 patients had
anaemia, mostly grade 2/3 (83%). Leucocytosis was present in 5
patients (42%), thrombocytosis in one patient, and both abnorm-
alities in another patient. One patient had received one platelet
transfusion, and 10 patients (83%) had received a median of 2
(range, 1–4) units of packed red blood cells (RBCs) within the
28 days prior to study entry. Bone marrow biopsies were performed
in 11 patients and showed increased cellularity in 7 patients (64%),
while 4 patients (36%) had decreased cellularity. Eleven patients
(92%) had received prior immunomodulating and/or antineoplastic
agents, most often hydroxycarbamide (50%) and thalidomide
(42%). Four patients (33%) had received anti-anaemic preparations
and one patient had undergone splenic radiation therapy.
Treatment and dosing. A total of 30 plitidepsin cycles were
administered with a median number of two cycles per patient
(range, 1–4). Median cumulative dose was 20.1 mg/m2 (range,
5.3–39.9 mg/m2), median dose intensity was 2.2 mg/m2/week
(range, 1.3–2.5 mg/m2 per week), and median relative dose
intensity was 86.8% (range, 52.6–100.7%).
A total of four cycles were delayed in four patients (that is, 40%
of the 10 patients who received more than one cycle), with a
median duration of 13.5 days (range, 7–15 days). Dose omissions
occurred in 2 cycles. All these dose delays/omissions were due to
causes unrelated to the study treatment: left ankle fracture, grade
4 neutropenia because of the disease, grade 3 oesophageal
varices haemorrhage, grade 2 blood creatinine increase and grade
2 bronchitis in the case of dose delays, and grade 2 rash macular
Figure 3. Effect of plitidepsin on P27 expression in human
hematopoietic cell lines. Human cell lines were incubated with
plitidepsin (1–10 nM) or in its absence (black columns) for 24 h. P27
mRNA expression was evaluated by real-time PCR and expressed as
the relative quantity versus control cells.
Figure 4. P27 mRNA levels in CD34+ cells. CD34+ from PMF patients
and healthy controls were isolated from peripheral blood and
analysed for p27 expression with real-time PCR. Results were
expressed as relative quantity by using an RNAse P for normal-
isation. The difference between the two groups was highly
significant (Po0.001).
Table 2. Demographic and baseline characteristics (n= 12)
Characteristic n %
Gender
Male 5 42
Female 7 58
Age (years) 69.5 (59–78)
ECOG PS
0 4 34
1 7 58
2 1 8
Myelofibrosis
Primary myelofibrosis 5 42
Post-polycythaemia vera 3 25
Post-essential thrombocythaemia 4 33
IPSS risk
High 9 75
Intermediate-2 2 17
Intermediate-1 1 8
Laboratory studies/physical examination at enrolment
Spleen size by ultrasound (cm2)a
o100 cm2 1 12
100–200 cm2 3 38
4200 cm2 4 50
Bone marrow biopsy cellularityb
Increased 7 64
Decreased 4 36
Haemoglobin (g/dl) 9.1 (8.0–11.9)
Platelet count (×109/l) 140.5 (32.0–677.0)
Leukocyte count (×109/l) 10.4 (1.8–51.2)
LDH (x ULN) 2.5 (0.8–12.0)
Previous therapy
Corticosteroids
Prednisone 7 58
Antineoplastic/immunomodulating
Anagrelide 3 25
Etanercept 1 8
Hydroxicarbamide 6 50
Lenalidomide 2 17
Rituximab 1 8
Thalidomide 5 42
Other immunosupressants 5 42
Anti-anaemic
Darbepoetin alpha 2 17
Epoetin alpha 2 17
Radiotherapy (spleen) 1 8
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group perfor-
mance status; IPSS, International Prognostic Scoring System; LDH, lactate
dehydrogenase; ULN, upper limit of normal. Data shown are n of patients
(%) except for age and laboratory data (median and range). aSpleen size by
ultrasound was missing in four patients. Palpable spleen size was as
follows: o10 cm (n= 4), 10–19 (n= 7) and ⩾ 20 cm (n= 1). bAssessment not
done in one patient.
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and grade 3 gastrointestinal bleeding in the case of dose
omissions. No dose reductions were required.
Efficacy. One of the 12 treated patients was excluded from
analysis of the primary efficacy endpoint. This patient received
one complete infusion of plitidepsin in Cycle 1, and had the
second infusion interrupted because of plitidepsin-related grade 3
chest and epigastric pain. Although the episode resolved a day
later, the patient refused to continue treatment and had no
disease evaluations done.
The primary analysis of best response according to International
Working Group for Myelofibrosis Research and Treatment in the
11 evaluable patients showed clinical improvement in one patient
(9.1%), stable disease in 9 patients (81.8%), and progressive
disease in one patient (9.1%). Characteristics of patients with
clinical improvement or stable disease are shown in Table 3.
The patient with clinical improvement was red cell transfusion-
dependent at baseline and converted to transfusion-independent
with treatment that persisted for more than 8 weeks. No partial or
complete remissions were observed. Therefore, RR according to
International Working Group for Myelofibrosis Research and
Treatment was 9.1% (95% CI, 0.2–41.3%). Median progression-
free survival in the 11 evaluable patients was 4.6 months (95% CI,
1.4–4.6 months). Median overall survival had not been reached at
cut-off date.
Eight patients underwent a short-lasting improvement of
splenomegaly, with maximum size reductions occurring during
the first two cycles of treatment (Table 3).
Safety. The safety population included all 12 treated patients.
Table 4 shows the main worst grade plitidepsin-related AEs; the
most common were fatigue, nausea, vomiting and muscular
weakness. Three patients had grade 3 AEs in one cycle each,
which comprised fatigue, upper abdominal pain and chest pain.
No grade 4 drug-related AEs occurred.
Three patients had isolated grade 1/2 prolonged electrocardio-
gram (ECG) QT interval of unknown relationship to plitidepsin in a
total of 7 cycles. One of the patients, diagnosed with high-risk
post-ET MF, had displayed abnormal ECG and chest exam (2/6
ejection murmur) at study entry. A second patient, diagnosed with
intermediate-2 PMF, had not reported previous cardiac complica-
tions or risk factors. The third patient, diagnosed with
intermediate-1 post-PV MF, had asymptomatic degenerative aortic
valvulopathy and mitral insufficiency at baseline and history of
transient ischaemic attacks.
The most common haematological abnormality irrespective of
relationship with plitidepsin treatment was anaemia, which
occurred in all patients at all cycles, followed by lymphopenia
and thrombocytopenia (Table 4).
All biochemical abnormalities were grade 1/2, and the only with
effect on treatment was one case of grade 2 creatinine increase,
which caused dose delay in one cycle (Table 4).
Two patients discontinued plitidepsin administration due to
events unrelated to the study treatment: grade 4 thrombocyto-
penia, and grade 3 pulmonary oedema, bronchopneumonia and
acute myocardial infarction.
DISCUSSION
Preclinical evaluation
Although the mechanism of action of plitidepsin remains to be
fully characterised, several targets have been identified in various
cellular models.15 Plitidepsin caused a dose-related arrest of cell
cycle and cell apoptosis following the induction of an early
oxidative stress, the activation of Rac1 GTPase and the inhibition
of protein phosphatases. The block of cell cycle at G0/G1 is largely
dependent on the activity of the CdK inhibitor p27, and an inverse
correlation between the expression level of p27 and the response
to plitidepsin has been demonstrated in human sarcoma cell
lines.16 Inhibition of cell viability occurs through the mitochondrial
apoptotic pathway, release of cytochrome c, PARP cleavage and
chromatin fragmentation.17,18 A sustained activation of members
of the MAPK family, including the serine/threonine kinases JNK
and p38 and possibly ERK, is rapidly induced by plitidepsin in
several tumour cell models and at least in part it is mediated by
Rac1,19,20 a member of the guanine triphosphatase family
downstream of the canonical Wnt signaling.21 Finally, plitidepsin
has anti-angiogenic properties and inhibits spontaneous and
vascular endothelial growth factor- and FGF-2-induced angio-
genesis in the chick allantoid assay.22–24 In a previous work using
the GATA-1low mouse model of MF,7 we showed that the MF trait
of the mice could be efficiently corrected by plitidepsin that, by
restoring the expression of Gata1 and p27(Kip1) in Gata1-low
haematopoietic cells, corrected the proliferation of marrow
progenitor cells in vitro and maturation of megakaryocytes
in vivo through a reduction of the levels of transforming growth
factor-beta and vascular endothelial growth factor abnormally
released by immature Gata1low megakaryocytes in the bone
marrow microenvironment. Microvessel density, fibrosis, bone
growth and marrow cellularity were normalised after plitidepsin
treatment of the mice and extramedullary haematopoiesis did not
develop in liver; notwithstanding, the abnormally reduced CXCR4
expression in Gata-1(low) progenitor cells was not improved by
plitidepsin. These preclinical results suggested that plitidepsin had
the potentiality to improve the MF phenotype of GATA-1low mice,
justifying further clinical development.25 In the current study, we
produce evidence that plitidepsin at low nanomolar concentra-
tions exerted potent antiproliferative activity and induced cell
cycle arrest and apoptosis in different cellular models of
JAK2V617F mutation and also prevented colony formation by
primary myeloproliferative neoplasm CD34+ cells. In the cell line
models, the effects of plitidepsin were consistent with an
upregulation of p27; however, although the level of p27 mRNA
were definitely lower in MF CD34+ cells than in control cells,
plitidepsin failed to normalise those levels in the human samples.
Overall, these data confirm the potent cytotoxic activity of
plitidepsin even against cells of myeloproliferative neoplasms,
although evidence of a preferential activity of the drug compared
to control cells was modest at all.
Clinical evaluation
The exploratory phase II trial that we report in this manuscript was
designed to evaluate the efficacy and safety of plitidepsin in
patients with PMF, post-PV MF or post-ET MF. Plitidepsin has
shown antitumour activity in several solid tumours26,27 as well as
in some malignant haematological disorders.28,29 The schedule
(q4wk) and dose (5 mg/m2 3-h i.v. infusion) used in this phase II
study had been effective and with an adequate benefit/risk ratio
in previous studies conducted in patients with various solid
tumours or multiple myeloma26–28,30
In the first stage of this trial, RR was 9.1%, which was lower than
the minimum protocol-defined threshold (20%) required for
further assessment of this regimen in this disease. Therefore, we
concluded that the current treatment regimen had low activity in
this population of patients with PMF, post-PV MF or post-ET MF.
Drugs such as hydroxyurea and interferon-alpha have modest
activity in controlling splenomegaly and leucocytosis in patients
with PMF, and favourable responses to thalidomide and
lenalidomide, chiefly in the form of improved haemoglobin and
platelet counts, have been reported in a small subset of
patients.31,32 Ruxolitinib (a JAK-1/2 inhibitor) was recently
approved for the treatment of intermediate and high-risk MF,
including PMF, post-PV MF or post-ET MF, with ⩾ 35 percent
reduction in splenic volume in 41.9% of patients, which was
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maintained for 48 weeks in the majority of patients with such a
response.5,33 In the current phase II exploratory trial, only one
patient had confirmed disease response (anaemia improvement),
whereas most patients had stable disease as best response.
Nevertheless, in the indication evaluated, stable disease frequently
equates with highly symptomatic disease for most patients,
usually characterised by poor quality of life. Finally, after taking
into account toxicity, quality/duration of response, patterns of
treatment failure and the activity observed with other drugs, it
was decided to terminate the study before going into the
second stage.
Plitidepsin was generally well tolerated and showed manage-
able toxicity when administered to this population of patients
with PMF, post-PV MF or post-ET MF. The most common toxicities
found in this study (fatigue, nausea/vomiting, and muscular
weakness) were consistent with those previously reported with
plitidepsin.26–28,30,34–36 In general, these toxicities were not dose-
limiting in the majority of patients, and were manageable by
appropriate dose modifications or administration delays. Three
cases of grade 1/2 prolonged QT ECG of unknown relationship
with plitidepsin were reported. Two of these three patients had
cardiac risk factors at baseline.
In conclusion, due to the modest antitumour activity reported,
plitidepsin given at a dose of 5 mg/m2 i.v. over 3 h on Day 1 and
15 q4wk to patients with PMF, post-PV MF or post-ET MF was
considered as not worthy of further clinical evaluation. The toxicity
profile of plitidepsin at this schedule of administration was
consistent with that observed with plitidepsin in other clinical
trials in patients with solid tumours and haematological disorders.
Preclinical results showed potent cytotoxic activity of plitidepsin
against myeloproliferative neoplasms that were not confirmed in
this exploratory phase II trial. A plausible reason could be that the
efficacy observed in mice was seen in a monogenic disorder
(GATA-low) that mirrors just one late mechanism of the disease
(megakaryocytes proliferation associated with deposition of
fibrosis)37 but does not reflect the likely multigenic, complex
pathogenesis of a stem cell disorder (not only megakaryocytes) as
is human MF.
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Table 3. Treatment response characteristics of patients treated with plitidepsin
Gender/age
(years)
MF type ECOG PS
BL/WPC
Plitidepsin
cycles
Best
responsea
PFS /OS
(months)
Plt/RBC transfusion (units) Spleen
reductionb (%)
Baseline On treatment
Male/77 Post PV 1/2 4 Clinical improvementc 4.6/4.6 0/2 0/0 21.4
Female/67 Post ET 1/2 1 SD 0.9+/1.7+ 0/1 1/1 0.0
Female/68 Post ET 1/2 4 SD 3.6+/4.5+ 0/2 0/2 22.2
Female/64 PMF 1/1 2 SD 1.0+/1.7+ 0/2 0/3 11.1
Female/67 PMF 0/1 3 SD 1.8+/5.1+ 0/1 0/2 ND
Male/72 PMF 1/3 2 SD 2.3+/2.3+ 0/2 0/4 35.0
Male/73 Post PV 1/1 2 SD 1.9+/2.1+ 1/2 0/10 53.3
Male/71 PMF 2/2 2 SD 2.0+/2.0+ 0/2 0/7 10.5
Male/64 PMF 0/0 3 SD 2.8+/3.8+ 0/0 0/10 7.7
Female/78 Post PV 0/1 2 SD 1.8+/4.8+ 0/0 0/0 22.2
Abbreviations: ECOG, Eastern Cooperative Oncology Group; IWG-MRT, International Working Group for Myelofibrosis Research and Treatment;
MF, myelofibrosis; ND, not determined; OS, overall survival; PFS, progression-free survival; Plt, platelet; post-ET, post-essential thrombocythaemia; post-PV,
post-polycythaemia vera; PMF, primary myelofibrosis; PS, performance status; RBC, red blood cell; SD, stable disease; WPC, worst per cycle.
aBest response as per IWG-MRT. bMaximal reduction from baseline by spleen palpation, which was reached within the first two cycles and persisted less
than 8 weeks in all patients measured. cTime to response was 1.9 months. +: Censored data.
Table 4. Main worst grade plitidepsin-related adverse events (⩾ 10%
of patients or cycles)
Adverse event Per patient (n= 12) Per cycle (n= 30)
Grade
1/2
Grade
3/4
Grade
1/2
Grade
3/4
n % n % n % n %
Haematologicala
Anaemia 3 25 9 75 13 43 17 57
Leukopenia 1 8 4 33 2 7 9 30
Lymphocytosis 3 25 — — 5 17 — —
Lymphopenia 5 42 4 33 13 43 6 20
Neutropenia 2 17 3 25 3 10 7 23
Thrombocytopenia 4 33 4 33 10 33 6 20
Non-haematologicala
ALT increase 8 67 — — 10 35 — —
AP increase 8 67 — — 21 72 — —
AST increase 8 67 — — 14 48 — —
CPK increase 4 33 — — 4 14 — —
Creatinine increase 6 50 — — 11 38 — —
Diarrhoea 2 17 — — 4 13 — —
ECG QT interval prolonged 3 25 — — 7 23 — −
Fatigue 4 33 2 17 6 20 2 7
Muscular weakness 3 25 — — 4 13 — —
Nausea 4 33 — — 5 17 — —
Vomiting 3 25 — — 3 10 — —
Abbreviations: ALT, alanine aminotransferase; AP, alkaline phosphatase;
AST, aspartate aminotransferase; CPK, creatine phosphokinase; ECG,
electrocardiogram. Apart from the adverse events shown in this table,
one patient each had grade 3 abdominal pain upper and grade 3 chest
pain in one cycle each. aLaboratory abnormalities are shown irrespective of
relationship with the plitidepsin treatment.
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